thiotepa has been researched along with Peripheral Nerve Diseases in 3 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer." | 9.09 | The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001) |
| "We evaluated the pharmacokinetics and pharmacodynamics of high-dose paclitaxel (HDP) monotherapy (825 mg/m2 continuous infusion over 24 h) with peripheral blood progenitor cell (PBPC) and G-CSF support in 17 women with metastatic breast cancer." | 5.09 | The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ( Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stubblefield, MD | 1 |
| Vahdat, LT | 2 |
| Balmaceda, CM | 2 |
| Troxel, AB | 2 |
| Hesdorffer, CS | 2 |
| Gooch, CL | 1 |
| Stern, BV | 1 |
| Baehring, JM | 1 |
| Kleopa, KA | 1 |
| Hochberg, FH | 1 |
| Papadopoulos, KP | 1 |
| Egorin, MJ | 1 |
| Huang, M | 1 |
| Kaufman, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer[NCT02215083] | Phase 1 | 0 participants (Actual) | Interventional | 2014-08-31 | Withdrawn (stopped due to Insufficient Patient Population) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thiotepa and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Topics: Action Potentials; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2005 |
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2001 |
1 other study available for thiotepa and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Demyelinating Diseases; Female; He | 2006 |